Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons

Journal of Biological Chemistry

Volumn 289, Issue 36, 2014, Pages 24845-24862

  Laprairie, Robert B ^a   Bagher, Amina M ^a   Kelly, Melanie E M ^a   Dupré, Denis J ^a   Denovan Wright, Eileen M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMICAL ACTIVATION; LIGANDS; MAMMALS; SIGNAL TRANSDUCTION;

CANNABINOID RECEPTORS; CELL CULTURE MODELS; HETEROLOGOUS EXPRESSION; INTRACELLULAR SIGNALING; SIGNAL TRANSDUCTION PATHWAYS; SIGNALING PATHWAYS; SPINY PROJECTIONS; SYNTHETIC CANNABINOIDS;

SIGNALING;

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; BETA ARRESTIN 1; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; 2-ARACHIDONYLGLYCEROL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZOXAZINE DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CYCLOHEXANOL DERIVATIVE; ENDOCANNABINOID; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PHOTOPROTEIN; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FUNCTIONAL SELECTIVITY; INTERNALIZATION; INTRACELLULAR SIGNALING; MOUSE; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CYTOLOGY; DENDRITIC SPINE; DRUG EFFECTS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETICS; METABOLISM; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACIDS; ARRESTIN; BENZOXAZINES; BLOTTING, WESTERN; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELLS, CULTURED; CORPUS STRIATUM; CYCLOHEXANOLS; DENDRITIC SPINES; DRONABINOL; ENDOCANNABINOIDS; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLYCERIDES; GTP-BINDING PROTEINS; LIGANDS; LUMINESCENT PROTEINS; MICE; MODELS, BIOLOGICAL; MORPHOLINES; NAPHTHALENES; NEURONS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 84906966570     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.557025     Document Type: Article

References (67)

1. Pertwee, R. G. (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict. Biol. 13, 147-159
2. Bosier, B., Muccioli, G. G., Hermans, E., and Lambert, D. M. (2010) Functionally selective cannabinoid receptor signaling: therapeutic implications and opportunities. Biochem. Pharmacol. 80, 1-12
3. Cupini, L. M., Costa, C., Sarchielli, P., Bari, M., Battista, N., Eusebi, P., Calabresi, P., and Maccarrone, M. (2008) Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol. Dis. 30, 186-189
4. Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T., and Lichtman, A. H. (2011) Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgeisa in mice. Pharmacol. Biochem. Behav. 99, 718-725
5. Pazos, M. R., Sagredo, O., and Fernández-Ruiz, J. (2008) The endocan-nabinoid system in Hungtington's disease. Curr. Pharm. Des. 14, 2317-2325
6. Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Aswad, D., Notcutt, W. G., Martinez-Orgado, J., Robson, P. J., Rohrback, B. G., Thiele, E., Whalley, B., and Friedman, D. (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55, 791-802
7. Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., and Colleoni, M. (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur. J. Pharmacol. 556, 75-83
8. Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., and Stephens, G. J. (2010) Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 332, 569-577
9. Cota, D., Marsicano, G., Lutz, B., Vicennati, V., Stalla, G. K., Pasquali, R., and Pagotto, U. (2003) Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab. Disord. 27, 289-301
10. Welch, S. P., and Eads, M. (1999) Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848, 183-190
11. Rubino, T., Viganò, D., Premoli, F., Castiglioni, C., Bianchessi, S., Zippel, R., and Parolaro, D. (2006) Changes in expression of G protein-coupled receptor kinases and β-arrestins in mouse brain during cannabinoid tolerance. Mol. Neurobiol. 33, 199-213
12. Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., and Berry, E. M. (2009) Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J. Hepatol. 51, 528-534
13. Kearn, C. S., Greenberg, M. J., DiCamelli, R., Kurzawa, K., and Hillard, C. J. (1999) Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem. 72, 2379-2387
14. Bosier, B., Hermans, E., and Lambert, D. (2008) Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br. J. Pharmacol. 155, 24-33
15. Breivogel, C. S., Selley, D. E., and Childers, S. R. (1998) Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with aongist-induced decreases in GDP affinity. J. Biol. Chem. 273, 16865-16873
16. Ryan, W., Singer, M., Razdan, R. K., Compton, D. R., and Martin, B. R. (1995) A novel class of potent tetrahydrocannabinols (THCS): 2′-yne-Δ8- and Δ9-THCS. Life Sci. 56, 2013-2020
17. Wiley, J. L., Compton, D. R., Dai, D., Lainton, J. A., Phillips, M., Huffman, J. W., and Martin, B. R. (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 285, 995-1004
18. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R., and Martin, B. R. (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270, 219-227
19. Falenski, K. W., Thorpe, A. J., Schlosburg, J. E., Cravatt, B. F., Abdullah, R. A., Smith, T. H., Selley, D. E., Lichtman, A. H., and Sim-Selley, L. J. (2010) FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after Δ9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 35, 1775-1787
20. Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., Pavón, F. J., Serrano, A. M., Selley, D. E., Parsons, L. H., Lichtman, A. H., and Cravatt, B. F. (2009) Selective blockade of 2-arachidonylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5, 37-44
21. Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., Thomas, E. A., Selley, D. E., Sim-Selley, L. J., Liu, Q. S., Lichtman, A. H., and Cravatt, B. F. (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113-1119
22. Glass, M., and Northup, J. K. (1999) Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol. 56, 1362-1369
23. Mukhopadhyay, S., and Howlett, A. C. (2005) Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol. Pharmacol. 67, 2016-2024
24. Bonhaus, D. W., Chang, L. K., Kwan, J., and Martin, G. R. (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287, 884-888
25. Lauckner, J. E., Hille, B., and Mackie, K. (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. U.S.A. 102, 19144-19149
26. Anavi-Goffer, S., Fleischer, D., Hurst, D. P., Lynch, D. L., Barnett-Norris, J., Shi, S., Lewis, D. L., Mukhopadhyay, S., Howlett, A. C., Reggio, P. H., and Abood, M. E. (2007) Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J. Biol. Chem. 282, 25100-25113
27. Georgieva, T., Devanathan, S., Stropova, D., Park, C. K., Salamon, Z., Tollin, G., Hruby, V. J., Roeske, W. R., Yamamura, H. I., and Varga, E. (2008) Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur. J. Pharmacol. 581, 19-29
28. Bakshi, K., Mercier, R. W., and Pavlopoulos, S. (2007) Interaction of a fragment of the cannabinoid CB1 receptor C terminus with arrestin-2. FEBS Lett. 581, 5009-5016
29. Varga, E. V., Georgieva, T., Tumati, S., Alves, I., Salamon, Z., Tollin, G., Yamamura, H. I., and Roeske, W. R. (2008) Functional selectivity in cannabinoid signaling. Curr. Mol. Pharmacol. 1, 273-284
30. Singh, S. N., Bakshi, K., Mercier, R. W., Makriyannis, A., and Pavlopoulos, S. (2011) Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2. Biochemistry 50, 2223-2234
31. Jin, W., Brown, S., Roche, J. P., Hsieh, C., Celver, J. P., Kovoor, A., Chavkin, C., and Mackie, K. (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J. Neurosci. 19, 3773-3780
32. van der Lee, M. M., Blomenröhr, M., van der Doelen, A. A., Wat, J. W., Smits, N., Hanson, B. J., van Koppen, C. J., and Zaman, G. J. (2009) Pharmacological characterization of receptor redistribution and β-arrestin recruitment assays for the cannabinoid receptor 1. J. Biomol. Screen. 14, 811-823
33. 2screening assay for the "non"-β-arrestin binding CB1 receptor. J. Biomol. Screen. 14, 371-380
34. Bosier, B., Tilleux, S., Najimi, M., Lambert, D. M., and Hermans, E. (2007) Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J. Neurochem. 102, 1996-2007
35. Bosier, B., Lambert, D. M., and Hermans, E. (2008) Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells. FEBS Lett. 582, 3861-3867
36. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V. C., Sharp, A. H., Persichetti, F., Cattaneo, E., and MacDonald, M. E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799-2809
37. Laprairie, R. B., Kelly, M. E., and Denovan-Wright, E. M. (2013) Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease. Neuropharmacology 72, 47-57
38. Milligan, G., Unson, C. G., and Wakelam, M. J. (1989) Cholera toxin treatment produces down-regulationof the &alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs). Biochem. J. 262, 643-649
39. McKenzie, F. R., and Milligan, G. (1991) Cholera toxin impairment of opioid-mediated inhibitionof adenylate cyclase in neuroblastoma x glioma hybrid cells is due to a toxin-induced decrease in opioid receptor levels. Biochem. J. 275, 175-181
40. 1receptor complexes. Eur. J. Pharmacol. 721, 341-354
41. Fernández-Ruiz, J., Gómez, M., Hernández, M., de Miguel, R., and Ramos, J. A. (2004) Cannabinoids and gene expression during development. Neurotox. Res. 6, 389-401
42. 1) gene transcription. Br. J. Pharmacol. 167, 1583-1595
43. Hudson, B. D., Hébert, T. E., and Kelly, M. E. (2010) Physical and functional interaction between CB1 cannabinoid receptors and β2-adrenoceptors. Br. J. Pharmacol. 160, 627-642
44. Lavoie, C., Mercier, J. F., Salahpour, A., Umapathy, D., Breit, A., Villeneuve, L. R., Zhu, W. Z., Xiao, R. P., Lakatta, E. G., Bouvier, M., and Hébert, T. E. (2002) β1/β2-adrenergic receptor heterodimerization regulates β2- adrenergic receptor internalization and ERK signaling efficacy. J. Biol. Chem. 277, 35402-35410
45. Dupré, D. J., Thompson, C., Chen, Z., Rollin, S., Larrivée, J. F., Le Gouill, C., Rola-Pleszczynski, M., and Stanková, J. (2007) Inverse agonist-induced signaling and down-regulation of the platelet-activating factor receptor. Cell. Signal. 19, 2068-2079
46. Ramsay, D., Kellett, E., McVey, M., Rees, S., and Milligan, G. (2002) Homoand hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem. J. 365, 429-440
47. James, J. R., Oliveira, M. I., Carmo, A. M., Iaboni, A., and Davis, S. J. (2006) A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. Nat. Methods 3, 1001-1006
48. Wu, H. Y., Hudry, E., Hashimoto, T., Uemura, K., Fan Z. Y., Berezovska, O., Grosskreutz, C. L., Bacskai, B. J., and Hyman, B. T. (2012) Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid β revealed by novel FRET assay. J. Neurosci. 32, 5298-5309
49. Knowles, R. B., Chin, J., Ruff, C. T., and Hyman, B. T. (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrilary tangles: implications for MAPkinase activation in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 58, 1090-1098
50. Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M. R., Resel, E., Palazuelos, J., Julien, B., Salazar, M., Börner, C., Benito, C., Carrasco, C., Diez-Zaera, M., Paoletti, P., Díaz-Hernández, M., Ruiz, C., Sendtner, M., Lucas, J. J., de Yébenes, J. G., Marsicano, G., Monory, K., Lutz, B., Romero, J., Alberch, J., Ginés, S., Kraus, J., Fernández-Ruiz, J., Galve-Roperh, I., and Guzmán, M. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119-136
51. Daigle, T. L., Kearn, C. S., and Mackie, K. (2008) Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 54, 36-44
52. Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Madabushi, S., Reiter, E., Premont, R. T., Lichtarge, O., and Lefkowitz, R. J. (2006) β-Arrestin-dependent, G-protein-independent ERK1/2 activation by the β2 adrenergic receptor. J. Biol. Chem. 281, 1261-1273
53. Obara, Y., Okano, Y., Ono, S., Yamauchi, A., Hoshino, T., Kurose, H., and Nakahata, N. (2008) βγ subunits of G(i/o) suppress EGF-induced ERK5 phosphorylation, whereas ERK1/2 phosphorylation is enhanced. Cell. Signal. 20, 1275-1283
54. Simpson, J. N., and McGinty, J. F. (1995) Forskolin induces preproenkephalin and preprodynorphin mRNA in rat striatum as demonstrated by in situ histochemistry. Synapse 19, 151-159
55. Gu, G., Rojo, A. A., Zee, M. C., Yu, J., and Simerly, R. B. (1996) Hormonal regulation of CREB phosphorylation anteroventral periventricular nucleus. J. Neurosci. 16, 3035-3044
56. Dalton, G. D., and Howlett, A. C. (2012) Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells. Br. J. Pharmacol. 165, 2497-2511
57. McIntosh, B. T., Hudson, B., Yegorova, S., Jollimore, C. A., and Kelly, M. E. (2007) Agonist-dependent cannabinoid receptor signaling in human trabecular meshwork cells. Br. J. Pharmacol. 152, 1111-1120
58. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., and Hanus, L. O. (2007) Cannabidiol: recent advances. Chem. Biodivers. 4, 1678-1692
59. Przybyla, J. A., and Watts, V. J. (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine DRL receptor heterodimers. J. Pharmacol. Exp. Ther. 332, 710-719
60. 2. Pharmacol. Rev. 62, 588-631
61. Kondo, S., Kondo, H., Nakane, S., Kodaka, T., Tokumura, A., Waku, K., and Sugiura, T. (1998) 2-Arachidonylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues and evidence for its generation through Ca2+-dependent and -independent mechanisms. FEBS Lett. 429, 152-156
62. 1receptor is a 2-arachidonylglycerol receptor: structure-activity relationship of 2-arachidonylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274, 2794-2801
63. 1receptor adaptation after cessation of long-term cannabinoid administration. Mol. Pharmacol. 70, 986-996
64. 1receptor adaptation and regulation of transcription. Life Sci. 92, 446-452
65. 1receptor signaling and adaptation in a central nervous system region-dependent manner. Biol. Psychiatry 71, 714-724
66. 1receptors in hippocampal neurons. J. Neurosci. 21, 2425-2433
67. Wu, D. F., Yang, L. Q., Goschke, A., Stumm, R., Brandenburg, L. O., Liang, Y. J., Höllt, V., and Koch, T. (2008) Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J. Neurochem. 104, 1132-1143